Effects of erythropoietin administration in training athletes and possible indirect detection in doping control

Medicine and Science in Sports and Exercise

Volumn 31, Issue 5, 1999, Pages 639-645

  Audran, Michel ^a   Gareau, Raynald ^b   Matecki, Stephane ^b   Durand, Fabienne ^b   Chenard, Claire ^b   Sicart, Marie Therese ^b   Marion, Benedicte ^b   Bressolle, Françoise ^b  

^a UNIV MONTPELLIER   (France)

^b NONE

Author keywords

Athletes; Recombinant human erythropoietin; Repeated subcutaneous administrations

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; ATHLETE; BLOOD LEVEL; DRUG ABUSE; DRUG EFFECT; EXERCISE; FEMALE; HEART RATE; HUMAN; NORMAL HUMAN; OXYGEN CONSUMPTION; SPORT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BICYCLING; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; PHYSICAL EDUCATION AND TRAINING; PHYSICAL FITNESS; RESPIRATION;

EID: 0032941959     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005768-199905000-00003     Document Type: Article

References (29)

1. ANNABLE, L., P. M. COTES, and M. V. MUSSET. The Second International Reference Preparation of Epo, human, urinary, for bioassay. Bull. W.H.O. 47:99-112, 1972.
2. ASHAI, N. I., E. P. PAGANINI, and J. M. WILSON. Intravenous versus subcutaneous dosing of Epoetin: a review of the literature. Am. J. Kidney Dis. 22(Suppl. 1):23-31, 1993.
3. BEAVER, W. L., K. WASSERMAN, and B. J. WHIPP. A new method for detecting anaerobic threshold by gas exchange. J. Appl. Physiol. 60:2020-2027, 1986.
4. BERGLUND, B., and B. EKBLOM. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy males. J. Int. Med. 229:125-130, 1991.
5. BESARAB, A. Optimizing epoetin therapy in end-stage renal disease: the case of subcutaneous administration. Am. J. Kidney Dis. 22(Suppl. 1): 13-22, 1993.
6. BOMMER, J., M. KUGEL, W. SCHOEPPE, et al. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Contrib. Nephrol. 66:85-93, 1988.
7. BRESSOLLE, F., M. AUDRAN, R. GAREAU, R. D. BAYNES, A. DUVALLET, and R. GOMENI. Population pharmacodynamics for monitoring epoetin in athletes. Clin. Drug Invest. 14:233-242, 1997.
8. BROCKMÖLLER, J., J. KÖCHLING, W. WEBER, M. LOOBY, I. ROOTS, and H. H. NEUMAYER. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br. J. Clin. Pharmacol. 34:499-508, 1992.
9. BRUGNARA, C., G. M. COLELLA, J. CREMINS, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte Hb content and iron-deficient erythropoiesis. J. Lab. Clin. Med. 123:660-667, 1994.
10. BUCHFUHRER, M. J., J. E. HANSEN, and T. E. ROBINSON. Optimizing the exercise protocol for cardiopulmonary assessment. J. Appl. Physiol. 55:1558-64, 1983.
11. CASONI, I., G. RICCI, E. BALLARIN, et al. Hematological indices of erythropoietin administration in athletes. Int. J. Sports Med. 14: 307-311, 1993.
12. ECKARDT, K. U., A. KURTZ, P. HIRTH, P. SCIGALLA, L. WIECZOREK, and C. BAUER. Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Klin. Wochensch. 66:241-245, 1988.
13. EKBLOM, B., and B. BERGLUND. Effect of erythropoietin administration on maximal aerobic power in man. Scand. J. Med. Sci. Sports 1:88-93, 1991.
14. GAREAU, R., G. R. BRISSON, C. AYOTTE, M. AUDRAN, and J. L. CHANAL. A possible approach to erythropoietin doping detection. In: Blood Samples in Doping Control: Proceedings of the Second International Symposium on Drugs in Sports, P. Hemmersbach and K. I. Birkeland (Eds.). 1993 Aug 29-31: Oslo: Pensumtjenest, 1994, pp. 141-151.
15. GAREAU, R., M. AUDRAN, R. D. BAYNES, et al. Erythropoietin abuse in athletes. Nature 380:113, 1996.
16. IMAI, N., A. KAWAMURA, M. HIGUCHI, et al. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J. Biochem. 107:352-359, 1990.
17. JELKMAN, W. Biology of erythropoietin. Clin. Invest. 72:S3-S10, 1994.
18. KICMAN, A. T., and D. A. COWAN. Peptides hormones and sport: misuse and detection. Br. Med. Bull. 48:496-517, 1992.
19. KLAUSEN, T., F. DELA, E. HIPPE, and H. GALBO. Diurnal variations of serum erythropoietin in trained and untrained subjects. Eur. J. Appl. Physiol. Occup. 67:545-548, 1993.
20. KOHRT, W. M., J. S. O'CONNOR, and J. S. SKINNER. Longitudinal assessment of responses by triathletes to swimming, cycling, and running. Med. Sci. Sports Exerc. 21:569-75, 1989.
21. KOURY, M. J., and M. C. BONDURANT. The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210:649-663, 1992.
22. MARKHAM, A., and H. M. BRYSON. Epoetin alfa: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49:232-254, 1995.
23. MCMAHON, F. G., R. VARGAS, M. RYAN, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76:1718-1722, 1990.
24. PK-FIT, VERSION 1.0, R.D.P.P., MONTPELLIER, FRANCE.
25. SINGBART, G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin. Invest. 72:S36-S43, 1994.
26. SOUILLARD, A., M. AUDRAN, F. BRESSOLLE, R. GAREAU, A. DUVALLET, and J. L. CHANAL. Recombinant human erythropoietin and pharmacodynamic parameters in athletes: interest of blood sampling for doping control. Br. J. Clin. Pharmacol. 42:355-360,1996.
27. VEYS, N., and S. RINGOIR. The subcutaneous administration route of epoetin: advantages, pain at the injection site and patient acceptance. Int. J. Artif. Organs 16:1-3, 1993.
28. WIDE, L., C. BENGTSSON, and G. BIRGEGARD. Circadian rhythm of erythropoietin in human serum. Br. J. Haematol. 72:85-90, 1989.
29. WIDE, L., C. BENGTSSON, B. BERGLUND, and B. EKBLOM. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med. Sci. Sports Exerc. 27:1569-1576, 1995.